Myomo’s orthotic arm device scores CE mark

Myomo's MyoPro device helps people move their paralyzed or weakened arms by detecting neurological signals and amplifying them.

Medical robotics company Myomo has earned a CE mark for its lightweight, wearable device that restores movement in paralyzed or weakened arms and hands. The company will begin its rollout in Germany.

The MyoPro orthosis is designed to let patients who have suffered a stroke, spinal cord injury or have another neuromuscular disability control their arm or hand using their own muscles. It is a powered brace that detects a patient’s neurological signals and amplifies them, driving motors in the brace to move the arm and hand.

“The MyoPro powered brace allows individuals suffering from paralysis or stroke to perform routine daily activities,” said Myomo CEO Paul Gudonis, in a statement. “Gaining CE Mark approval is an important milestone for our Company and for the many people in Europe who will now be able to experience the benefits of MyoPro as they struggle with upper limb paralysis.”


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

“We are currently working with our partner Ottobock to plan our European launch beginning in Germany,” Gudonis said. “Myomo recently conducted sales and clinical training for Ottobock staff, which has begun evaluating patients for the MyoPro device. With revenue of over a billion Euros and operations in 50 countries, Ottobock is a global market leader in technical orthopedics and prosthetics.”

The news comes after the Cambridge, Massachusetts-based company went public via a “crowdsourced IPO.” In June, Myomo completed a $5 million IPO under Regulation A+, a provision of the Jumpstart our Business Startups Act that makes it easier for smaller companies to access capital.

While Myomo missed its $15 million target, the funds will support sales, marketing and its international expansion. They will also go toward developing its product pipeline, including a pediatric version of the MyoPro device.

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The National Institutes of Health has tapped the genomics firm Color to help participants understand and act on their results.

In a $72 million deal, Inex Innovations Exchange and Nova Satra will combine their laboratory, R&D and distribution arms.